NASD · Healthcare · Biotechnology · USA
Savara Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Savara Inc is a clinical stage biopharmaceutical company developing treatments for rare lung disorders. Its sole product candidate, molgramostim inhalation solution (MOLBREEVI), is an investigational inhaled therapy in trials for autoimmune pulmonary alveolar proteinosis, administered using a proprietary nebulizer delivery system.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Savara Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
135 more in this industry show a wider margin of safety.
We do not publish a verdict on SVRA yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-10-19 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.